Holen Sie sich die Stockscreener-App
1.38
1.43%
-0.02
Handel nachbörslich:
1.39
0.01
+0.72%
Opko Health Inc Aktie (OPK) Neueste Nachrichten
Is OPKO Health Inc. a good long term investmentExplosive trading opportunities - jammulinksnews.com
What drives OPKO Health Inc. stock priceSuperior stock selection - jammulinksnews.com
OPKO Health Inc. Stock Analysis and ForecastTremendous portfolio expansion - jammulinksnews.com
11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey
What analysts say about OPKO Health Inc. stockSkyrocketing returns - Autocar Professional
How high can OPKO Health Inc. stock price go in 2025Predictable Return Stock Picks - beatles.ru
OPKO Health (NASDAQ:OPK) Stock Rating Upgraded by LADENBURG THALM/SH SH - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) Receives $2.75 Consensus Price Target from Analysts - MarketBeat
H.C. Wainwright Reiterates a Buy Rating on Opko Health (OPK), Keeps the PT at $3 - MSN
Opko Health (OPK) Has a New Rating from Ladenburg Thalmann & Co. - The Globe and Mail
Capital Advisors Inc. OK Increases Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO Health and Entera Bio Announce Abstract on PK/PD of - GlobeNewswire
OPKO Health and Entera Bio abstract selected for ESPEN Congress - StreetInsider
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress - Yahoo Finance
Breakthrough: First-Ever Oral Tablet Could Replace Daily Injections for Short Bowel Syndrome Treatment - Stock Titan
Investor Network: OPKO Health, Inc. to Host Earnings Call - ACCESS Newswire
OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025 - MSN
OPKO Health's Russell 2000 Defensive Index Inclusion: A Catalyst for Strategic Revaluation - AInvest
10 Best Healthcare Penny Stocks to Buy According to Analysts - Insider Monkey
OPKO and Entera to present data on oral obesity treatment at ENDO 2025 - Investing.com Nigeria
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting - OPKO Health, Inc.
Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT - Yahoo Finance
13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey
Shareholders in OPKO Health (NASDAQ:OPK) have lost 51%, as stock drops 6.5% this past week - simplywall.st
Here's Why You Should Retain OPKO Health Stock in Your Portfolio - MSN
Quote - OPKO Health, Inc.
Bone Cancer Drugs Market Set to Witness Significant Growth - openPR.com
Bank of America Corp DE Has $855,000 Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO Health: Strong Pipeline Of Drugs, But Not Rushing To Buy (NASDAQ:OPK) - Seeking Alpha
ModeX assembles advisory board for antibody development By Investing.com - Investing.com India
ModeX assembles advisory board for antibody development - Investing.com
OPKO Health's ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - The Manila Times
OPKO Health's (OPK) ModeX Therapeutics Forms Scientific Advisory Board - StreetInsider
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - GlobeNewswire
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - GlobeNewswire Inc.
2.06%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):